The FDA has approved Edwards Lifesciences' Autus Size-Adjustable Valve, the first surgical pulmonary valve designed to grow with pediatric congenital heart patients. The device can be expanded inside the body from 13 to 22 millimeters via a minimally invasive balloon catheter, potentially sparing children from multiple open-heart surgeries. It is also the first FDA-approved valve to use synthetic polymeric leaflets rather than animal tissue, offering improved durability. A 62-patient pivotal study met all safety and efficacy endpoints with zero device-related complications at 30 days.
FDA approval and review
- ▪The U.S. Food and Drug Administration reviewed the Autus Size-Adjustable Valve through its premarket approval process and previously granted it Breakthrough Device designation.
- ▪The U.S. Food and Drug Administration approved the Autus Size-Adjustable Valve on October 1, 2026, as the first surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease.
Size-adjustable design and expansion
- ▪The Autus Size-Adjustable Valve can be implanted at 13 millimeters in diameter for toddlers and expanded incrementally inside the body up to 22 millimeters using a balloon catheter.
- ▪The ability to expand the Autus Size-Adjustable Valve inside the body through a minimally invasive transcatheter procedure is designed to reduce the need for repeat open-heart surgeries as a child grows.
Synthetic polymeric leaflet material
- ▪The Autus Size-Adjustable Valve is the first FDA-approved heart valve of any kind to use synthetic polymeric material for its leaflets instead of animal-derived tissue.
- ▪The synthetic polymeric leaflets of the Autus Size-Adjustable Valve are designed to be more durable than animal tissue, which tends to harden, wear out, and break down faster in children.
Pivotal clinical study results
- ▪The pivotal study of the Autus Size-Adjustable Valve evaluated 62 pediatric patients across 12 U.S. hospitals, meeting its primary safety and effectiveness endpoints with no deaths, strokes, or blood clots.
- ▪In the pivotal clinical study, 100% of patients were free from device-related complications through 30 days and required no Autus valve reinterventions through six months.
- ▪Among patients who completed the one-year follow-up in the pivotal study, 100% demonstrated a right ventricular outflow tract mean gradient of 40 mmHg or less and no valve reinterventions.
Long-term and follow-up studies
- ▪Edwards Lifesciences plans to continue following pediatric patients who received the Autus Size-Adjustable Valve in clinical studies for 10 years.
- ▪A continued access study for the Autus Size-Adjustable Valve is currently underway as longer-term studies continue.
Prevalence of pediatric heart valve defects
- ▪Approximately 400,000 children are born in the United States each year with some form of congenital heart disease, with about 30 percent of those cases affecting the heart valves.
- ▪Pulmonary valve stenosis and atresia affect approximately 4,200 babies born in the United States every year, according to data from the Centers for Disease Control and Prevention.
Debatable claims
- ▪The FDA should prioritize rapid access over long-term data for breakthrough pediatric medical devices
- ▪The Autus valve's expandability will significantly improve pediatric patient quality of life
- ▪Synthetic polymer is superior to animal tissue for pediatric heart valves
Story comments
Loading comments…